adiponectin might have both direct and indirect actions on the metabolic cluster of major coronary risks and on insulin resistance (IR). Inflammatory markers, including highly sensitive C-reactive protein (hs-CRP) and interleukin-6, are associated with the risk of development of arteriosclerosis in both diabetic and non-diabetic patients. [9] [10] [11] [12] Reduced plasma adiponectin concentration has been found in patients with type 2 diabetes mellitus. 9, 11, 13, 14 These findings suggest that adiponectin might have anti-inflammatory properties and might act as an endogenous modulator for the development of metabolic syndrome and/or IR. Several studies have shown the effects of sarpogrelate on insulin-sensitization and/or increased plasma adiponectin level in diabetic patients with or without nephropathy and vasculopathy. [13] [14] [15] [16] [17] These effects of sarpogrelate might contribute not only to risk factor management but also to primary or secondary prevention of ASCDs; however, the insulin-sensitizing effects of sarpogrelate in non-diabetic patients with PAD have not been reported.
The aim of this study was to determine whether sarpogrelate has a persistent insulin-sensitizing effect by adiponectin modification in non-diabetic and non-medicated diabetic patients with PAD.
Methods

Study Subjects
Twenty-four symptomatic patients (19 males, 5 females; mean age 76±9 years [range, 50-88 years]) with PAD who were indicated for sarpogrelate hydrochloride (MitsubishiWell Pharma Co, Osaka, Japan) were enrolled ( Table 1) . All of the patients had PAD-related symptoms (Fontaine grade I in 16 patients (67%), and Fontaine grade II in 8 patients (33%)) with an ankle -brachial index (ABI) below 0.9. The exclusion criteria were: (1) contraindications for continuing sarpogrelate administration, such as severe hepatic dysfunction, mental disorder, bleeding tendency, malignancy or pregnancy, (2) need for oral administration of any drugs that might influence IR evaluation or have an indication for diabetic drug treatment, (3) end-stage renal failure, acute coronary syndrome, uncontrolled congestive heart failure or lethal arrhythmia, and (4) need for interventional and/or surgical revascularization for cardiovascular disease during the study period. All of the subjects gave written informed consent for participation in this study, and the study was carried out in accordance with the ethical guidelines of the hospital.
Complicated ASCDs in the subjects were CAD in 13 (54%), prior cerebrovascular disease in 6 (25%), and atherosclerotic valvular heart disease in 7 (29%). Major risk factors of CAD, diagnosed according to the latest diagnostic criteria, were hypertension in 10 (42%), diabetes mellitus in 4 (17%), hyperlipidemia in 14 (58%), hyperuricemia in 7 (29%), current smoking habit in 7 (29%) and familial history of CAD in 6 (25%). Mean body mass index (BMI, kg/m 2 ) was 23.1±2.6, and 5 (21%) of the patients were obese. Co-administered medications were calcium-channel blocker in 11 (46%), angiotensin II receptor blocker and/or angiotensin-converting enzyme inhibitor in 14 (58%), -blocker in 5 (21%), aspirin in 17 (71%), ticlopidine in 8 (33%), dipyridamole in 1 (4%), cilostazol in 3 (13%), beraprost sodium in 5 (21%), diuretics in 9 (38%) and statins in 8 (33%) ( Table 1) . Administration of these drugs was continued and unchanged throughout the study.
Study Protocol and Measurements
After on observation period of 3-5 days, oral administration of sarpogrelate hydrochloride at a dose of 300 mg (100 mg 3 times daily) was started. Acute effects (2 weeks protocol) on IR variables were investigated in all subjects, and then the chronic effects in 16 PAD patients who were followed in an out-hospital clinic (3 months protocol). Examined variables were (1) basic patient information including body weight (BW, kg) and BMI, systolic and diastolic blood pressures measured by the sphygmo-cuff method (mmHg), ABI, pulse wave velocity (PWV) measured by the impedance method (m/s), (2) IR and its related variables: fasting blood sugar (FBS, mg/dl), fasting immunoreactive insulin (IRI, U/ml), calculated homeostasis model assessment (HOMA-R) = FBS × IRI /405, total cholesterol (TC, mg/dl), triglyceride (TG, mg/dl), high-density lipoproteincholesterol (HDL-C, mg/dl), and (3) specific measurable values including hs-CRP (mg/dl), and adiponectin ( g/ml). Plasma adiponectin concentrations were determined by radioimmunoassay kit according to the manufacturer's instructions (Linco Research, St Charles, MO, USA). The concentrations of hs-CRP and lipid proteins, including TG, TC and HDL-C, were measured by standard methods. Laboratory-based values of plasma catecholamines (ng/ml) and serotonin (nmol/L, high performance liquid chromatography method) were also measured in selected patients (n=10). A standard laboratory-based blood examination, including white blood cell count, platelets count, liver and renal functions, was performed for confirming adverse effects of sarpogrelate administration.
Statistical Analysis
All data are expressed as mean ± SD Comparison of variables between the 2 groups was assessed by unpaired Student's t-test and comparison among multiple subgroups was performed by analysis of variance with Bonferroni's test. Categorical variables were analyzed by the chi-square test. Correlations between 2 variables were analyzed by single linear regression analysis. A p-value <0.05 was considered to be statistically significant.
Results
In all subjects, sarpogrelate was administered without adverse side-effects. Fontaine grades after sarpogrelate administration were I in 16 (67%) and II in 8 (33%).
Sarpogrelate Administration
Short-Term (2 Weeks) Effects (Table 2 ) Slight decreases in systolic blood pressure and TC (from 196±72 to 186± 63 mg/dl (p=0.03)) were observed at 2 weeks after sarpogrelate administration, but there was no change in diastolic blood pressure, TG (from 160±105 to 142±69 mg/dl (p=NS)), ABI, PWV or HDL-C. A significant decrease in fasting IRI (from 14.2±9.8 to 9.9±3.3 U/ml (p=0.03)) with unchanged FBS values resulted in decreased HOMA-R values (from 3.73±2.72 to 2.53±0.99 (p=0.024)) (Fig 1) . However, there was no change in either adiponectin (from 10.5±9.3 to 10.0±9.2 g/ml (p=NS)) (Fig 1) or hs-CRP (from 0.14±0.12 to 0.20±0.15 mg/dl (p=NS)) in the shortterm.
Long-Term (3 Months) Effects (Table 3 ) Similar changes were observed in fasting IRI (from 16.0±10.3 to 10.9± 2.4 U/ml after 2 weeks and to 9.2±2.0 U/ml (p=0.03) after 3 months), HOMA-R (from 4.30±2.83 to 2.52±0.72 after 2 months and to 2.40±0.74 after 3 months (p=0.025)), and adiponectin (from 8.11±4.13 to 8.21±4.22 g/ml after 2 weeks and to 9.64±4.37 g/ml after 3 months (p=0.027)) (Fig 2) , despite no significant changes in related variables: BW (from 60±9 to 59±10 kg after 3 months (p=NS)), blood pressure, ABI, PWV, FBS (from 109±26 to 106±26 mg/dl after 3 months (p=NS)), TC (from 187±43 to 191±45 mg/dl after 3 months (p=NS)), TG (from 159±108 to 159± 94 mg/dl after 3 months (p=NS)), HDL-C (from 45±13 to 48±13 mg/dl after 3 months (p=NS)), hs-CRP (from 0.18± 0.18 to 0.16±0.14 mg/dl after 2 weeks and to 0.11± 0.08 mg/dl after 3 months (p=NS)). There were no significant changes in platelet count (from 21.3±9.4 to 21.5±8.2 10 3 / l after 2 weeks and to 18.9±6.9 10 3 / l after 3 months (p=NS)) or plasma serotonin (from 6.76±2.40 to 7.10± 3.61 nmol/L after 2 weeks and to 8.38±2.76 nmol/L after 3 months (p=NS)). 
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Correlation of HOMA-R and Adiponectin Values
All of the examined HOMA-R had a significant correlation with all of the examined adiponectin (Fig 3, log adiponectin =-0.57× log HOMA-R +1.14, p<0.001, r=-0.441). However, no significant correlation was found between the changes in HOMA-R and the changes in adiponectin.
Discussion
Serotonin is a naturally occurring vasoactive substance and is involved in the vascular inflammation that leads to atherosclerosis. Sarpogrelate hydrochloride is a selective serotonin 2A antagonist and is clinically used as an antiplatelet agent for cutaneous ulcer healing, pain control and improving peripheral ischemia in PAD. Various favorable cardiovascular pleiotropic actions of sarpogrelate have been reported. [1] [2] [3] [4] [5] A recent preliminary study by Yamakawa et al 14 showed a chronic increase in circulatory adiponectin and reduced HOMA-R in a small number of patients with treated diabetes mellitus (n=8) following sarpogrelate administration. Considering the wide range of actions of adiponectin on ASCDs, [13] [14] [15] [16] [17] [18] sarpogrelate might have a beneficial effect on risk factor control and secondary prevention of ASCDs. Actually, evaluation of IR and adiponectin concentration in diabetic patients is a difficult task, therefore it is of interest to know whether sarpogrelate has similar long-term effects in non-diabetic patients.
The main results of this study are (1) sarpogrelate administration had both acute and chronic effects on IR (IRI or HOMA-R modification) in PAD patients, (2) adiponectin was increased after 3 months of sarpogrelate administration, and (3) all of the examined HOMA-R had a significant correlation with all of the examined adiponectin. These results suggest that sarpogrelate had a persistent insulin-sensitizing effect through adiponectin modification, and that sarpogrelate has beneficial effects, at least in non-diabetic and non-medicated diabetic patients with PAD.
Measurement of IR in Multiple Risk Factor Syndrome
An individual clustering of both ASCDs and coronary risk factors has been conceptually proposed as multiple risk factor syndrome, metabolic syndrome X, 19 deadly quartet, 20 IR syndrome, 21 or visceral fat syndrome, 22 and IR has been postulated to play a key role in all these syndromes. Therefore, a therapeutic modality in ASCDs that has a favorable effect on IR will be beneficial.
DeFronzo et al 23 have defined IR as a state of reduced glucose uptake under the constant condition of insulin secretion. The M value of the glucose clamp method is the most appropriate value to fulfill the definition of IR; however, conveniently measuring IR in the clinical setting is not always an easy task. 23, 24 Therefore, reactive hyperinsulinemia with or without glucose challenge is generally used as an index for IR. HOMA-R and the fasting IRI value are the most convenient laboratory-based indices for IR. However, various factors such as glucose absorption, renal function, insulin excretion, insulin space, and glucose toxicity must be kept in mind during its evaluation. Particularly in patients with treated diabetes mellitus, exaggerated IR enhancement and changes during diabetic treatment might influence IR evaluation. The subjects in this study were all non-diabetic patients or non-medicated diabetes patients, and all of them had normal renal function. Furthermore, BW, TC and TG remained constant during long-term administration of sarpogrelate, so the possibility of secondary improvement by regression of diabetes mellitus was ruled out.
Adiponectin and Inflammatory Markers
Measurement of adiponectin is another option for estimating the development of arteriosclerosis, because adiponectin may play both direct and indirect roles in IR and arteriosclerosis-related inflammatory markers. [6] [7] [8] [9] Reduced plasma adiponectin concentrations have been found in patients with diabetes mellitus. 9, 11, 13, 14 These findings suggest that adiponectin might have anti-inflammatory properties and might act as an endogenous modulator for the development of metabolic syndrome. Actions of sarpogrelate on insulin sensitization and/or increased plasma adiponectin concentrations have been recently reported. [13] [14] [15] However, adiponectin values in nondiabetic patients remain higher than in patients with diabetes mellitus, 9, 11, 25 so it is of interest to know whether adiponectin has a similar effect on IR in non-diabetic patients. We found a similar long-term effect on both IR and adiponectin, as shown in a preliminary by Yamakawa et al 14 in patients with treated diabetes mellitus. However, the changes of both variables were smaller in non-diabetic patients, as shown by us previously. 6, 7 Interestingly, there is a time discrepancy between the significant changes in IR variables and adiponectin. HOMA-R and IRI values decreased immediately after sarpogrelate administration without an increase in adiponectin. We can not comment on the precise mechanism of the time discrepancy, although there are several possibilities: (1) higher prevalence of complicated ASCDs other than PAD might influence the prolonged depression in adiponectin levels, and (2) IR is changed through another mechanism (eg, changes in food intake and rest after hospitalization).
Changes of adiponectin
The present study is a small, observational study in 1 cardiovascular center. Prospective, double-blind studies must be performed to obtain firmer conclusions regarding the effectiveness of sarpogrelate for primary and/or secondary prevention of ASCDs. We also failed to show normalization of hs-CRP (an inflammatory marker) in this study; however, the small number of subjects with multiple complicated ASCDs and the minimal changes in adiponectin induced by sarpogrelate might have influenced the results.
IR Modification by Serotonin 2A Receptor Antagonist
Sarpogrelate, commercially available as an antiplatelet agent, has various beneficial cardiovascular effects, such as enhancement of ischemic tolerance, 1,2 induction of NOs, 3 and increased collateral circulation. 4 Our results also showed novel actions of sarpogrelate on IR and adiponectin modification, which are supported by the results of a recent experimental investigation in OLETF rats 26 and clinical data from diabetic patients. 14 The mechanisms of these beneficial actions on IR remain unclear. Nomura et al 13 have reported that levels of platelet activation markers (platelet-P-selectin and platelet-CD63) and endothelial injury markers (soluble E-selectin and sVCAM-1) were higher and adiponectin was lower in patients with diabetes mellitus than in normal subjects. In addition, these changes improved after sarpogrelate treatment. Furthermore, significant relationships of adiponectin concentration with levels of platelet activation markers and endothelial injury markers have been found. 13 Thus, improvement in platelet activation and endothelial dysfunction after sarpogrelate treatment may contribute to the improvement of IR.
The persistent vasodilator action of sarpogrelate and the recovery of peripheral perfusion in PAD have been speculated to improve the reduced blood flow in the large skeletal muscles and to enhance their glucose uptake. However, our subjects had relatively mild PAD-related symptoms, and PWV was unchanged.
Another possibility is a canceling of IR exacerbation by the enhanced serotonin 27 or by an increase in serotoninrelated catecholamine in ASCDs; 28 however, our study failed to show any influence of these parameters. We examined catecholamine concentrations in some patients (n=10), but none showed a significant change in catecholamine concentrations during the period of sarpogrelate administration. Therefore, the direct action on catecholamine will be minimal, at least, for IR modification. We also failed to reveal modification of plasma serotonin level during sarpogrelate administration; however, serotonin sampling is difficult clinically, as shown by the contradictory data on plasma serotonin level during sarpogrelate use. 29 Furthermore, as shown experimentally, [2] [3] [4] tissues that are serotonin-rich are mainly vascular beds, mast cells, and sympathetic nerve endings, so the value of circulatory serotonin might not have pathophysiological meaning.
Study Limitations
First, as stated earlier, this study was observational in a single cardiovascular center with a small number of subjects. Although no medication or surgical procedure was added or changed in the subjects, we did not have a true control group (ie, PAD patients without diabetes mellitus and not receiving sarpogrelate in the same experimental period); therefore, the possibility of IR regression by conventional therapy, such as exercise or food intake, can not be ruled out. This possibility was also supported by the fact that TC and blood pressure only changed in the initial 2-week short-term protocol (admission period). Second, the subjects in this study were limited to PAD patients with relatively mild symptoms. Another study is needed to determine whether sarpogrelate has beneficial effects in patients with more severe PAD or in patients with other ASCDs such as CAD and cerebrovascular disease. Third, we could not determine whether IR or adiponectin modification actually has a beneficial effect on ASCDs. Therefore, a multicenter double-blind study is needed to obtain firmer conclusions on the beneficial effect of sarpogrelate on ASCDs.
Conclusions
Sarpogrelate has a persistent insulin-sensitizing effect through adiponectin modification and might be beneficial for anti-atherosclerotic therapy, at least in non-diabetic and non-medicated diabetic patients with PAD.
